Oryzon to invest eur 20 million to develop new drugs
Catalan Economy
10 Sep 2009
Biotech company oryzon genomics has announced a four-year program to invest eur 20 million in the development of new drugs. oryzon ceo carlos buesa indicated that the company would use the resources to strengthen its research on biomarkers and antibody therapy.
oryzon recently opened its new 2,300-square-meter corporate headquarters in cornellà de llobregat (barcelona), with an investment of eur 2.5 million. the company expects revenue of eur 8 million for its current fiscal year.
source: expansión catalunya, 08/09/09
Related News and Success stories.
-
18 Mar 2026
See more €50 million investment to triple DFactory Barcelona’s innovation space€50 million investment to triple DFactory Barcelona’s innovation space
-
17 Mar 2026
See more Catalonia advances a €10 million quantum initiative to enhance secure communications in EuropeCatalonia advances a €10 million quantum initiative to enhance secure communications in Europe
-
11 Mar 2026
See more Eurecat technology center marks 10 years with €1.25 billion impact on Catalonia’s economyEurecat technology center marks 10 years with €1.25 billion impact on Catalonia’s economy
-
02 Mar 2026
See more Catalonia ranks 8th globally for attracting tech and digital foreign investment projectsCatalonia ranks 8th globally for attracting tech and digital foreign investment projects
